

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

DECEMBER 4, 2014

VOL. 371 NO. 23

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

Laura Mauri, M.D., Dean J. Kereiakes, M.D., Robert W. Yeh, M.D., Priscilla Driscoll-Shempp, M.B.A., Donald E. Cutlip, M.D., P. Gabriel Steg, M.D., Sharon-Lise T. Normand, Ph.D., Eugene Braunwald, M.D., Stephen D. Wiviott, M.D., David J. Cohen, M.D., David R. Holmes, Jr., M.D., Mitchell W. Krucoff, M.D., James Hermiller, M.D., Harold L. Dauerman, M.D., Daniel I. Simon, M.D., David E. Kandzari, M.D., Kirk N. Garratt, M.D., David P. Lee, M.D., Thomas K. Pow, M.D., Peter Ver Lee, M.D., Michael J. Rinaldi, M.D., and Joseph M. Massaro, Ph.D., for the DAPT Study Investigators*

ABSTRACT

BACKGROUND

Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain.

METHODS

Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding.

RESULTS

A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; $P < 0.001$) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; $P < 0.001$). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; $P < 0.001$). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; $P = 0.05$). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, $P = 0.001$). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment.

CONCLUSIONS

Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.)

The authors' affiliations are listed in the Appendix. Address reprint requests to Dr. Mauri at the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at lmauri1@partners.org.

*A complete list of investigators and committee members in the Dual Antiplatelet Therapy (DAPT) study is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on November 16, 2014, at NEJM.org.

N Engl J Med 2014;371:2155-66.

DOI: 10.1056/NEJMoal409312

Copyright © 2014 Massachusetts Medical Society.

MILLIONS OF PATIENTS WORLDWIDE undergo coronary stenting each year for the treatment of ischemic heart disease.^{1,2} Although drug-eluting stents reduce the rate of restenosis as compared with bare-metal stents, there is concern that drug-eluting stents may be associated with a risk of stent thrombosis beyond 1 year after treatment.³ Stent thrombosis is rare, yet it is frequently associated with myocardial infarction and may be fatal.³ Furthermore, ischemic events, such as myocardial infarction, stroke, or death from cardiovascular causes, that are unrelated to the treated coronary lesion may also occur beyond 1 year.^{4,5}

The use of dual antiplatelet therapy in which a P2Y₁₂-receptor inhibitor is combined with aspirin is critically important for the prevention of coronary stent thrombosis, and this therapy is currently recommended for 6 to 12 months after implantation of a drug-eluting stent.^{6,7} Although some observational studies suggest that extending dual antiplatelet therapy beyond 1 year is associated with a reduced risk of myocardial infarction after the placement of a drug-eluting stent,⁸ several trials have shown an increased risk of bleeding without a reduction in the incidence of myocardial infarction with longer therapy.⁹⁻¹² Whether treatment with dual antiplatelet therapy beyond 1 year reduces the rate of either coronary-stent thrombosis or ischemic events occurring in an area remote from the stent has not been determined by an adequately powered, randomized trial.

The Dual Antiplatelet Therapy (DAPT) study was an international, multicenter, randomized, placebo-controlled trial that was designed to determine the benefits and risks of continuing dual antiplatelet therapy beyond 1 year after the placement of a coronary stent.

METHODS

STUDY DESIGN

The design of the DAPT study has been described previously.¹³ The trial was designed in response to a request from the Food and Drug Administration (FDA) to manufacturers of coronary stents and was conducted under an investigational-device exemption through a public-private collaboration involving the FDA, eight stent and pharmaceutical manufacturers who funded the study (see the Supplementary Appendix, available with the full text of this article at NEJM.org), and the Harvard

Clinical Research Institute (HCRI). The stent manufacturers who funded the trial had contributing roles in the design of the trial and in the collection of the data, as detailed in the Supplementary Appendix. The HCRI was responsible for the scientific conduct of the trial and an independent analysis of the data.

To facilitate enrollment, a single, uniform randomized trial was designed that incorporated five individual component studies (see the Supplementary Appendix). Patients were enrolled in the trial either by the HCRI or through one of four postmarketing surveillance studies that were designed to collect similar clinical data in similar patient populations. Each contributing study followed uniform randomization criteria and the same follow-up schedule for assessments, as specified by the overall DAPT study protocol. A single clinical-events committee whose members were unaware of the group assignments adjudicated events, and an unblinded, independent, central data and safety monitoring committee oversaw the safety of all patients. The institutional review board at each participating institution approved the study.

The first three authors and the last author wrote the manuscript under the coordination of the HCRI, had full access to the data, and vouch for the integrity of the analyses presented and for the fidelity of this report to the trial protocol (available at NEJM.org). The manuscript was provided to the funding manufacturers for review in advance of publication; however, they did not have the right to make changes, except with regard to individual manufacturer confidential information.

STUDY POPULATION

We enrolled patients older than 18 years of age who were candidates for dual antiplatelet therapy after treatment with FDA-approved drug-eluting or bare-metal stents. Details of the inclusion and exclusion criteria are provided in the Supplementary Appendix. Each patient provided written informed consent at the time of enrollment.

The population included in the primary analysis for this report comprised only patients who were treated with drug-eluting stents (results in patients who received bare-metal stents are not included in this analysis) (Fig. 1). Drug-eluting stents included sirolimus-eluting stents (Cypher, Cordis), zotarolimus-eluting stents (Endeavor, Medtronic), paclitaxel-eluting stents (TAXUS, Boston



A video summary
is available at
NEJM.org




Figure 1. Enrollment, Randomization, and Follow-up.

Patients were enrolled within 72 hours after stent placement. They were followed for 12 months while they received open-label treatment with thienopyridine plus aspirin and were then randomly assigned to receive thienopyridine therapy or placebo (each in addition to aspirin) for an additional 18 months. The randomized treatment period ended at 30 months; thereafter, patients continued taking aspirin only and were followed for another 3 months. Although the number of patients with available data on clinical follow-up is reported in each group, the coprimary efficacy end points were analyzed with the last available follow-up information in the intention-to-treat population, which included all patients who underwent randomization. GUSTO denotes Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.

Table 1. Characteristics of Patients Who Were Treated with Drug-Eluting Stents and Who Underwent Randomization.*

| Characteristic | Continued Thienopyridine (N = 5020) | Placebo (N = 4941) |
|--|--|-----------------------|
| Patients | | |
| Age — yr | 61.8±10.2 | 61.6±10.1 |
| Female sex — no. (%) | 1242 (24.7) | 1284 (26.0) |
| Nonwhite race — no./total no. (%)† | 438/4918 (8.9) | 419/4847 (8.6) |
| Hispanic or Latino ethnic group — no./total no. (%)† | 159/4924 (3.2) | 159/4847 (3.3) |
| Weight — kg‡ | 91.5±19.7 | 91.5±19.4 |
| Body-mass index§ | 30.5±5.8 | 30.6±5.8 |
| Diabetes mellitus — no./total no. (%) | 1556/5006 (31.1) | 1481/4927 (30.1) |
| Hypertension — no./total no. (%) | 3796/5006 (75.8) | 3649/4934 (74.0) |
| Current cigarette smoker or within past year — no./total no. (%) | 1222/4965 (24.6) | 1210/4893 (24.7) |
| Stroke or TIA — no./total no. (%) | 155/5006 (3.1) | 169/4931 (3.4) |
| Congestive heart failure — no./total no. (%) | 238/5001 (4.8) | 223/4926 (4.5) |
| Peripheral arterial disease — no./total no. (%) | 284/4937 (5.8) | 284/4857 (5.8) |
| Prior PCI — no./total no. (%) | 1518/4995 (30.4) | 1529/4928 (31.0) |
| Prior CABG — no./total no. (%) | 568/5012 (11.3) | 581/4930 (11.8) |
| Prior myocardial infarction — no./total no. (%) | 1092/4953 (22.0) | 1026/4870 (21.1) |
| Indication for PCI — no. (%) | | |
| STEMI | 534 (10.6) | 511 (10.3) |
| NSTEMI | 776 (15.5) | 767 (15.5) |
| Unstable angina¶ | 838 (16.7) | 825 (16.7) |
| Stable angina | 1882 (37.5) | 1870 (37.8) |
| Other | 990 (19.7) | 968 (19.6) |
| Any risk factor for stent thrombosis — no./total no. (%) | 2410/4751 (50.7) | 2389/4685 (51.0) |
| Region — no. (%) | | |
| North America | 4502 (89.7) | 4416 (89.4) |
| Europe | 402 (8.0) | 405 (8.2) |
| Australia or New Zealand | 116 (2.3) | 120 (2.4) |
| Thienopyridine drug at start of open-label period — no. (%)** | | |
| Clopidogrel | 3275 (65.2) | 3230 (65.4) |
| Prasugrel | 1745 (34.8) | 1711 (34.6) |
| Type of drug-eluting stent at index procedure — no. (%) | | |
| Everolimus-eluting | 2345 (46.7) | 2358 (47.7) |
| Paclitaxel-eluting | 1350 (26.9) | 1316 (26.6) |
| Zotarolimus-eluting | 642 (12.8) | 622 (12.6) |
| Sirolimus-eluting | 577 (11.5) | 541 (10.9) |
| >1 type | 106 (2.1) | 104 (2.1) |
| No. of treated lesions | 1.30±0.55 | 1.29±0.54 |
| No. of treated vessels | 1.11±0.33 | 1.12±0.34 |
| No. of stents | 1.47±0.75 | 1.45±0.75 |
| Minimum stent diameter — no. (%) | | |
| <3 mm | 2341 (46.6) | 2293 (46.4) |
| ≥3 mm | 2679 (53.4) | 2648 (53.6) |
| Total stent length — mm | 27.70±16.77 | 27.43±17.02 |

Table 1. (Continued.)

| Characteristic | Continued Thienopyridine (N = 5020) | Placebo (N = 4941) |
|---|--|-----------------------|
| Lesions | | |
| Treated vessel†† | | |
| Native coronary-artery lesions | 6396/6586 (97.1) | 6204/6407 (96.8) |
| Left main | 55/6586 (0.8) | 55/6407 (0.9) |
| Left anterior descending | 2715/6586 (41.2) | 2586/6407 (40.4) |
| Right | 2153/6586 (32.7) | 2057/6407 (32.1) |
| Circumflex | 1473/6586 (22.4) | 1506/6407 (23.5) |
| Venous graft | 154/6586 (2.3) | 173/6407 (2.7) |
| Arterial graft | 36/6586 (0.5) | 30/6407 (0.5) |
| Modified ACC–AHA lesion class B2 or C — no./total no. (%)‡‡ | 2754/6335 (43.5) | 2643/6137 (43.1) |

* Plus–minus values are means \pm SD. There were no significant differences between the two groups except with respect to hypertension ($P=0.03$). For most variables, 0 to 3% of the patients had missing values; however, 3.5% of the patients were missing data on lesion class. CABG denotes coronary-artery bypass grafting, NSTEMI non–ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, and TIA transient ischemic attack.

† Race and ethnic group were self-reported.

‡ Data on body weight were available for 5009 patients in the group that was randomly assigned to continued thienopyridine therapy and 4931 in the group that was assigned to placebo.

§ The body-mass index is the weight in kilograms divided by the square of the height in meters. Data were available for 4973 in the group that was randomly assigned to continued thienopyridine therapy and 4901 in the group that was assigned to placebo.

¶ This category included unstable angina without reported elevation of cardiac enzymes.

|| Risk factors for stent thrombosis are listed in Table S1 in the Supplementary Appendix.

** At the time of randomization (12 months after the start of the open-label period), 63.5% of the patients who were subsequently assigned to continue receiving thienopyridine were taking clopidogrel, and 34.7% were taking prasugrel; the corresponding rates among the patients who were subsequently assigned to the placebo group were 65.2% and 34.8%.

†† A total of 6594 lesions were treated in the thienopyridine group and 6413 in the placebo group.

‡‡ The definitions of class B2 and class C lesions according to the modified American College of Cardiology (ACC)–American Heart Association (AHA) criteria are provided in the Supplementary Appendix.

Scientific), and everolimus-eluting stents (Xience, Abbott Vascular; and Promus, Boston Scientific). It was recommended that all patients receive either clopidogrel at a maintenance dose of 75 mg daily or prasugrel at a maintenance dose of 10 mg daily (with a dose of 5 mg daily recommended in patients who weighed less than 60 kg).¹³ The recommended maintenance dose of aspirin was 75 to 162 mg daily, to be taken indefinitely.

STUDY PROCEDURES

Patients were enrolled within 72 hours after placement of a stent and were given open-label aspirin and thienopyridine for 12 months. At 12 months, patients who had not had a major adverse cardiovascular or cerebrovascular event, repeat revascularization, or moderate or severe bleeding and had been adherent to thienopyridine therapy (defined as having taken 80 to 120% of the drug

without an interruption of longer than 14 days) were eligible for randomization (Fig. 1).

Eligible patients continued taking aspirin and were randomly assigned, in a 1:1 ratio, to continued thienopyridine therapy or to placebo for an additional 18 months (months 12 to 30 after enrollment). A computer-generated randomization schedule stratified patients according to the type of stent they had received (drug-eluting vs. bare-metal), hospital site, type of thienopyridine drug, and presence or absence of at least one prespecified clinical or lesion-related risk factor for stent thrombosis (see Table S1 in the Supplementary Appendix).¹³ After the end of the randomized treatment period, we followed patients for a 3-month observational period during which they took aspirin alone (months 30 to 33 after enrollment) so that we could assess the effect of discontinuation of thienopyridine on the rates of end-point events.

Table 2. Stent Thrombosis and Major Adverse Cardiovascular and Cerebrovascular Events.*

| Outcome | Continued Thienopyridine (N=5020) | Placebo (N=4941) | Hazard Ratio, Thienopyridine vs. Placebo (95% CI)†‡ | P Value†‡ |
|---|--------------------------------------|---------------------|---|-----------|
| | <i>no. of patients (%)</i> | | | |
| Stent thrombosis‡ | 19 (0.4) | 65 (1.4) | 0.29 (0.17–0.48) | <0.001 |
| Definite | 15 (0.3) | 58 (1.2) | 0.26 (0.14–0.45) | <0.001 |
| Probable | 5 (0.1) | 7 (0.1) | 0.71 (0.22–2.23) | 0.55 |
| Major adverse cardiovascular and cerebrovascular events§ | 211 (4.3) | 285 (5.9) | 0.71 (0.59–0.85) | <0.001 |
| Death | 98 (2.0) | 74 (1.5) | 1.36 (1.00–1.85) | 0.05 |
| Cardiac | 45 (0.9) | 47 (1.0) | 1.00 (0.66–1.52) | 0.98 |
| Vascular | 5 (0.1) | 5 (0.1) | 0.98 (0.28–3.39) | 0.98 |
| Noncardiovascular | 48 (1.0) | 22 (0.5) | 2.23 (1.32–3.78) | 0.002 |
| Myocardial infarction | 99 (2.1) | 198 (4.1) | 0.47 (0.37–0.61) | <0.001 |
| Stroke | 37 (0.8) | 43 (0.9) | 0.80 (0.51–1.25) | 0.32 |
| Ischemic | 24 (0.5) | 34 (0.7) | 0.68 (0.40–1.17) | 0.16 |
| Hemorrhagic | 13 (0.3) | 9 (0.2) | 1.20 (0.50–2.91) | 0.68 |
| Type uncertain | 0 | 1 (<0.1) | — | 0.32 |

* At 12 months after placement of a drug-eluting stent, patients were randomly assigned to receive either continued thienopyridine therapy plus aspirin or placebo plus aspirin for 18 months. Data are presented for the intention-to-treat population. The primary analysis was performed on data from the period of 12 to 30 months after enrollment, and the study coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events. Percentages are Kaplan–Meier estimates.

† The hazard ratios and P values were stratified according to geographic region (North America, Europe, or Australia and New Zealand), thienopyridine drug received at the time of randomization, and presence or absence of risk factors for stent thrombosis. P values were calculated with the use of a log-rank test.

‡ Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.

§ The end point of major adverse cardiovascular and cerebrovascular events was a composite of death, myocardial infarction, or stroke.

END POINTS

The coprimary efficacy end points were the cumulative incidence of definite or probable stent thrombosis (as assessed according to the Academic Research Consortium definitions)¹⁴ and of major adverse cardiovascular and cerebrovascular events (defined as the composite of death, myocardial infarction, or stroke) during the randomized treatment period (month 12 to month 30). The primary safety end point was the incidence of moderate or severe bleeding during this same period (as assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] criteria).¹⁵ Bleeding was also evaluated according to the Bleeding Academic Research Consortium (BARC) criteria.¹⁶ More detailed definitions of the end points are provided in the Supplementary Appendix. After the primary analysis had been completed, a second

clinical-events committee whose members were unaware of the treatment assignment was convened to adjudicate noncardiovascular causes of death.

STATISTICAL ANALYSIS


The primary efficacy analysis was a superiority analysis performed with the use of the log-rank test, with stratification according to geographic region (North America, Europe, or Australia and New Zealand), thienopyridine drug received at the time of randomization, and presence or absence of risk factors for stent thrombosis. We controlled the two-sided family-wise error rate of 0.05 across the two coprimary end points using the Hochberg–Benjamini method.¹⁷ With this method, the null hypothesis of randomized treatment equivalence is rejected if significance is achieved for both end points at a two-sided alpha level of 0.05 or for

one end point at a two-sided alpha level of 0.025. We assumed that the annual event rates with placebo would be 0.5% for stent thrombosis and 2.9% for major adverse cardiovascular and cerebrovascular events, that the hazard ratios with continued thienopyridine therapy versus placebo would be 0.45 for stent thrombosis and 0.75 for major adverse cardiovascular and cerebrovascular events, and that the annual loss to follow-up would be no more than 3%. Given these assumptions, we calculated that with a sample of 9800 patients undergoing randomization and receiving drug-eluting stents, the study would have at least 85% power for the superiority analysis. This sample size was reduced from the 12,196 specified in the original protocol because of changes made in statistical parameters before enrollment was completed and without inspection of the study data (as described in the Supplementary Appendix).

The primary safety analysis was a noninferiority analysis performed with the use of the Farrington–Manning risk-difference approach.¹⁸ Assuming an annualized rate for moderate or severe bleeding of 1.9% and an absolute noninferiority margin of 0.8%, at a one-sided alpha level of significance of 0.025, we calculated that a sample size of 9960 patients would give the study 80% power to detect noninferiority.

The primary analyses of major adverse cardiovascular and cerebrovascular events and stent thrombosis were performed on data from all patients who underwent randomization and were treated with drug-eluting stents (the intention-to-treat population). Kaplan–Meier estimates of the cumulative incidence of each end point are presented according to study group, with two-sided 95% confidence intervals of stratified hazard ratios. Data for patients who did not have an endpoint event were censored for the analysis of that end point at the time of the last known contact or at 30 months, whichever was earlier. Secondary analyses included an examination of the same end points in all the patients over the course of the 21-month postrandomization period, the last 3 months of which the patients were not receiving the randomized treatment, and hazards before and after discontinuation of the study drug were assessed for qualitative differences.

The primary noninferiority assessment of bleeding was performed on data from patients who underwent randomization, were treated with drug-eluting stents, and completed at least 17 months



of follow-up (the minimum window allowed for the 18-month postrandomization visit) or had a moderate or severe bleeding event. Bleeding events are presented as binary rates. The hazard ratio for moderate or severe bleeding is also presented as a post hoc descriptive analysis.

To account for missing data, we repeated the treatment comparisons with data from all patients who underwent randomization using multiple-imputation¹⁹ logistic-regression modeling, with baseline covariates (50 imputations) for missing




Figure 3. Cumulative Incidence of Major Adverse Cardiovascular and Cerebrovascular Events, According to Study Group.

Cumulative incidence curves are shown for the primary effectiveness outcome of major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) in the intention-to-treat population. P values were calculated with the use of the stratified log-rank test. The number at risk was defined as the number of subjects who had not had the event of interest and who were available for subsequent follow-up. The numbers at risk at the start of final 33-month visit (i.e., 20 months after randomization) were 4336 in the group that had been assigned to continued thienopyridine therapy and 4217 in the group that had been assigned to placebo. The inset shows the same data on an enlarged y axis.

data on the primary end points. We also assessed the consistency of the effect of treatment on the primary end points in subgroups defined according to 14 prespecified factors assessed at baseline.

RESULTS

STUDY POPULATION

Between August 13, 2009, and July 1, 2011, a total of 25,682 patients at 452 sites in 11 countries were enrolled in the DAPT study, of whom 22,866 received a drug-eluting stent. Among these patients, 5261 (23.0%) were not eligible for randomization after 12 months of follow-up, 7644 (33.4%) were eligible but did not undergo randomization (see Table S2 in the Supplementary Appendix), and 9961 (43.6%) underwent randomization (Fig. 1). Among those who were eligible but did not undergo randomization, the most common reason

for not undergoing randomization was withdrawal of consent during the year between enrollment and randomization (76.0%).

The baseline characteristics of the patients who were treated with drug-eluting stents and underwent randomization were similar in the two study groups (Table 1). Overall, 26.0% presented with acute myocardial infarction, and 50.9% had at least one clinical or lesion-related risk factor for stent thrombosis (Table S1 in the Supplementary Appendix). The rates of discontinuation of the study drug did not differ significantly at 30 months between the group that continued thienopyridine therapy and the group that received placebo (21.4% and 20.3%, respectively; $P = 0.18$).

EFFICACY END POINTS

During the period from month 12 to month 30 (the primary-analysis period), among all patients who underwent randomization, the group that continued thienopyridine, as compared with the group that received placebo, had a significantly lower cumulative incidence of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; $P < 0.001$) and of major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; $P < 0.001$) (Table 2 and Fig. 2 and 3). Continued thienopyridine therapy was associated with a lower cumulative incidence of myocardial infarction than was placebo (2.1% vs. 4.1%; hazard ratio, 0.47 [95% CI, 0.37 to 0.61]; $P < 0.001$) (Fig. S1 in the Supplementary Appendix); myocardial infarction that was not related to stent thrombosis (1.8% vs. 2.9%; hazard ratio, 0.59; $P < 0.001$) accounted for 55% of the treatment benefit. The two groups had similar rates of death from cardiac causes (0.9% and 1.0%, respectively; $P = 0.98$), death from vascular causes (0.1% in each group, $P = 0.98$), and stroke (0.8% and 0.9%, respectively; $P = 0.32$). The rate of death from any cause was 2.0% with continued thienopyridine therapy and 1.5% with placebo (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; $P = 0.05$) (Fig. S2 in the Supplementary Appendix). The results after multiple imputation were consistent with those from the primary analysis (hazard ratio for stent thrombosis, 0.27; $P < 0.001$; and hazard ratio for major adverse cardiovascular and cerebrovascular events, 0.77; $P = 0.002$) (Table S3a in the Sup-

Table 3. Bleeding End Point during Month 12 to Month 30.*

| Bleeding Complications | Continued Thienopyridine (N=4710) | Placebo (N=4649) | Difference | Two-Sided P Value for Difference |
|---------------------------|-----------------------------------|------------------|----------------------------|----------------------------------|
| | no. of patients (%) | | percentage points (95% CI) | |
| GUSTO severe or moderate† | 119 (2.5) | 73 (1.6) | 1.0 (0.4 to 1.5) | 0.001 |
| Severe | 38 (0.8) | 26 (0.6) | 0.2 (-0.1 to 0.6) | 0.15 |
| Moderate | 81 (1.7) | 48 (1.0) | 0.7 (0.2 to 1.2) | 0.004 |
| BARC type 2, 3, or 5 | 263 (5.6) | 137 (2.9) | 2.6 (1.8 to 3.5) | <0.001 |
| Type 2 | 145 (3.1) | 72 (1.5) | 1.5 (0.9 to 2.1) | <0.001 |
| Type 3 | 122 (2.6) | 68 (1.5) | 1.1 (0.6 to 1.7) | <0.001 |
| Type 5 | 7 (0.1) | 4 (0.1) | 0.1 (-0.1 to 0.2) | 0.38 |

* The primary safety end point was moderate or severe bleeding as assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. The one-sided test of noninferiority (based on a noninferiority margin of 0.8%) was calculated according to the Farrington–Manning approach. Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥ 510 days after randomization or who had any adjudicated bleeding event at or before 540 days). Patients could have had more than one bleeding episode. The secondary analysis of bleeding, as assessed according to the criteria of the Bleeding Academic Research Consortium (BARC), is shown according to subtype in Table S5 in the Supplementary Appendix.

† One-sided $P=0.70$ for noninferiority.

plementary Appendix), as were the findings when the analysis period included the 3 months after discontinuation of the study drug (Table S4 in the Supplementary Appendix).

SAFETY END POINTS

The rate of moderate or severe bleeding during the primary-analysis period was significantly higher in the group that continued to receive thienopyridine therapy than in the placebo group (2.5% vs. 1.6%; hazard ratio 1.61 [95% CI, 1.21 to 2.16]; $P=0.001$); treatment with thienopyridine did not meet the prespecified criterion for noninferiority to placebo ($P=0.70$) (Table 3). There was no significant difference between the randomized treatments with respect to severe bleeding according to the GUSTO criteria (0.81% with continued thienopyridine and 0.56% with placebo, $P=0.15$) or with respect to fatal bleeding (type 5 bleeding) according to the BARC criteria (0.15% and 0.09%, respectively; $P=0.38$). Additional details of the results regarding bleeding according to BARC subtype are provided in Table S5 in the Supplementary Appendix. The results after multiple imputation were consistent with those from the main analysis (between-group difference in the risk of moderate or severe bleeding, 0.98%; $P=0.73$ for noninferiority) (Table S3b in

the Supplementary Appendix), as were the findings when the analysis period included the 3 months after study drug discontinuation (Table S6 in the Supplementary Appendix).

MORTALITY

During the primary-analysis period (month 12 to month 30), all-cause mortality was 2.0% in the group that continued to receive thienopyridine and 1.5% in the placebo group (hazard ratio, 1.36; $P=0.05$). During the secondary-analysis period (month 12 to month 33), all-cause mortality was 2.3% versus 1.8% (hazard ratio, 1.36; $P=0.04$) (Fig. S2 and Table S4 in the Supplementary Appendix), with the rate of death from noncardiovascular causes (1.1% vs. 0.6%; hazard ratio, 1.80; $P=0.01$) accounting for the difference in rates between the two analysis periods. Among the deaths from noncardiovascular causes, bleeding-related deaths (11 deaths in the group that continued to receive thienopyridine vs. 3 deaths in the placebo group, $P=0.06$) were related mainly to fatal trauma (7 deaths vs. 2 deaths, $P=0.07$). The number of cancer-related deaths differed significantly between the groups (31 vs. 14, $P=0.02$) and was mediated by bleeding in the case of three patients in the thienopyridine group (Table S7 in the Supplementary Appendix).

Among patients with a history of cancer at the time of enrollment in the study, 22 more patients were randomly assigned to the thienopyridine group than to the placebo group (Table S8 in the Supplementary Appendix), and a blinded review of cancer-related deaths identified a between-group imbalance in the number of patients who underwent randomization in whom cancer had been diagnosed before enrollment (8 vs. 1) (Table S9 in the Supplementary Appendix). When these patients were excluded in a post hoc sensitivity analysis, the differences in mortality were no longer significant (Table S10 in the Supplementary Appendix).

ADDITIONAL ANALYSES

The effect of continued thienopyridine therapy versus placebo on the rates of the primary end points and on the rate of myocardial infarction was consistent across most subgroups (Fig. S3 in the Supplementary Appendix). Hazards after discontinuation of thienopyridine therapy are provided in Table S11 in the Supplementary Appendix.

DISCUSSION

Among patients receiving drug-eluting coronary stents, continued treatment with thienopyridine and aspirin, as compared with aspirin alone, beyond 1 year reduced the risk of stent thrombosis and of major adverse cardiovascular and cerebrovascular events. This treatment benefit was driven by concurrent reductions in myocardial infarction related to the stent and occurring in other locations. A longer duration of thienopyridine treatment was associated with a greater risk of bleeding, although severe or fatal bleeding was uncommon and the rate did not differ significantly between the study groups.

The DAPT study included a large proportion of patients who had risk factors for stent thrombosis, including many who had received a stent for treatment of a myocardial infarction. Across almost all patients and lesion types, continued thienopyridine therapy was associated with reductions in the risk of both coprimary end points. In previous studies, different stents^{20,21} and P2Y12 inhibitors²² have been associated with varied rates of stent thrombosis and myocardial infarction; in this study, the use of thienopyridine beyond 1 year reduced the risks of both outcomes across all stent and drug types. Although

the results of previous studies vary with respect to the risk of discontinuation of thienopyridine after 6 months,^{10-13,23,24} the current study detected an increased risk of myocardial infarction (both stent-related and non-stent-related) in both study groups during the first 3 months after discontinuation. Future evaluation of thienopyridine therapy with an aim toward reducing the risks of cardiovascular events beyond the duration of this study may be warranted.

An unexpected finding was that the number of deaths from any cause during the treatment period was higher in the group that continued to receive thienopyridine than in the group that received placebo, a difference that was driven by an increase in the number of deaths from non-cardiovascular causes in the thienopyridine group. The rate of diagnosis of cancer did not differ significantly after randomization; however, there were more cancer-related deaths among patients treated with continued thienopyridine than among those who received placebo, a finding that may have reflected a chance imbalance in patients with known cancer before enrollment. Although one study comparing long-term thienopyridine therapy with placebo in patients with lacunar stroke identified an unexpected increase in mortality,²⁵ other large, randomized studies involving patients with coronary artery disease have not identified either increased or decreased risks of death.²⁶⁻²⁸

Several limitations of the study should be considered. First, only patients who were adherent to therapy and who did not have a major adverse cardiovascular or cerebrovascular event, stent thrombosis, or moderate or severe bleeding in the first year underwent randomization, a study design that may have selected for patients who were at lower risk for late adverse events. Second, although we did not quantify the net effect of ischemic and bleeding events, a decision analysis suggests that small absolute differences in the rates of cardiovascular events may be sufficient²⁹ to counterbalance bleeding risks. Third, although the study included four different metal-platform, durable polymer, drug-eluting stents and two platelet P2Y12 inhibitors, whether the treatment benefits observed will be generalizable to other stent types^{30,31} or non-thienopyridine P2Y12 inhibitors^{32,33} is unknown. In addition, since patients were not randomly assigned to a specific thienopyridine drug or stent

type, direct comparisons between different stent types or drugs may be confounded, and within-subgroup estimates of treatment effect may be underpowered.

In conclusion, among patients treated with drug-eluting stents, continuation of thienopyridine-plus-aspirin therapy, as compared with aspirin therapy alone, beyond 1 year reduced the risks of ischemic events. The reduction in the risk of ischemic events was consistent across stent type and specific thienopyridine drug used and

was evident regardless of the risk of stent thrombosis. The clinical benefit of extended thienopyridine treatment was tempered by an increase in bleeding events.

Supported by Abbott, Boston Scientific, Cordis, and Medtronic, Bristol-Myers Squibb–Sanofi Pharmaceuticals Partnership, Eli Lilly, and Daiichi Sankyo, and by a grant (1R01FD003870-01) from the Department of Health and Human Services.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Joanna Suomi for assistance in editing and formatting an earlier version of the manuscript and Wen-Hua Hsieh for assistance with statistical analysis.

APPENDIX

The authors' affiliations are as follows: Harvard Clinical Research Institute (L.M., R.W.Y., P.D.-S., D.E.C., J.M.M.), Brigham and Women's Hospital (L.M., E.B., S.D.W.), Harvard Medical School (L.M., R.W.Y., D.E.C., S.-L.T.N., E.B., S.D.W.), Massachusetts General Hospital (R.W.Y.), Harvard School of Public Health (S.-L.T.N.), Beth Israel Deaconess Medical Center (D.E.C.), and Boston University School of Public Health (J.M.M.) — all in Boston; Christ Hospital Heart and Vascular Center and the Lindner Center for Research and Education, Cincinnati (D.J.K.); Département Hospitalo-Universitaire Fibrosis, Inflammation, Remodeling, Hôpital Bichat, Assistance Publique–Hôpitaux de Paris, INSERM Unité 1148, and Université Paris Diderot — all in Paris (P.G.S.); National Heart and Lung Institute, Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, London (P.G.S.); Saint Luke's Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (D.J.C.); Mayo Clinic, Rochester, MN (D.R.H.); Duke University Medical Center, Durham (M.W.K.), and the Sanger Heart and Vascular Institute, Carolinas HealthCare System, Charlotte (M.J.R.) — both in North Carolina; St. Vincent Heart Center, Indianapolis (J.H.); University of Vermont, Burlington (H.L.D.); University Hospitals Case Medical Center, Cleveland (D.I.S.); Piedmont Heart Institute, Atlanta (D.E.K.); Lenox Hill Hospital, New York (K.N.G.); Stanford University, Stanford, CA (D.P.L.); Great Lakes Heart and Vascular Institute, St. Joseph, MI (T.K.P.); and Eastern Maine Medical Center, Bangor (P.V.L.).

REFERENCES

- Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics — 2013 update: a report from the American Heart Association. *Circulation* 2013;127(1):e6-e245. [Erratum, *Circulation* 2013;127(23):e841.]
- Togni M, Balmer F, Pfiffner D, Maier W, Zeiher AM, Meier B. Percutaneous coronary interventions in Europe 1992–2001. *Eur Heart J* 2004;25:1208-13.
- Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. *N Engl J Med* 2007;356:1020-9.
- Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* 2011;364:226-35. [Erratum, *N Engl J Med* 2011;365:2040.]
- Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. *Circulation* 2004;110:1226-30.
- Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation* 2011;124(23):e574-e651. [Erratum, *Circulation* 2012;125(8):e142.]
- Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35:2541-619.
- Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA* 2007;297:159-68.
- Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. *Circulation* 2012;125:2015-26.
- Park S-J, Park D-W, Kim Y-H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. *N Engl J Med* 2010;362:1374-82.
- Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. *JAMA* 2013;310:2510-22.
- Collet JP, Silvain J, Barthélémy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. *Lancet* 2014 July 15 (Epub ahead of print).
- Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the Dual Antiplatelet Therapy Study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. *Am Heart J* 2010;160:1035-41.
- Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007;115:2344-51.
- The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med* 1993;329:673-82.
- Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;123:2736-47.
- Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. *Stat Med* 1990;9:811-8.
- Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. *Stat Med* 1990;9:1447-54.
- Little RJA, Rubin DB. Statistical anal-

- ysis with missing data. New York: Wiley, 1987.
20. Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. *J Am Coll Cardiol* 2011;58:19-25.
21. Wijns W, Steg PG, Mauri L, et al. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. *Eur Heart J* 2014;35:2812-20.
22. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;357:2001-15.
23. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* 2013;382:1714-22.
24. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. *JAMA* 2008;299:532-9. [Erratum, *JAMA* 2008;299:2390.]
25. The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. *N Engl J Med* 2012;367:817-25.
26. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494-502. [Errata, *N Engl J Med* 2001;345:1506, 1716.]
27. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med* 2006;354:1706-17.
28. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001;358:527-33.
29. Garg P, Galper BZ, Cohen DJ, Yeh RW, Mauri L. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare duration of dual antiplatelet therapy after drug-eluting stents. *Am Heart J* ([http://www.ahjonline.com/article/S0002-8703\(14\)00661-9/abstract](http://www.ahjonline.com/article/S0002-8703(14)00661-9/abstract)).
30. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. *Lancet* 2014 September 12 (Epub ahead of print).
31. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. *J Am Coll Cardiol* 2012;59:1362-70.
32. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;361:1045-57.
33. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. *Am Heart J* 2014;167:437-44.

Copyright © 2014 Massachusetts Medical Society.

RECEIVE IMMEDIATE NOTIFICATION WHEN AN ARTICLE
IS PUBLISHED ONLINE FIRST

To be notified by e-mail when *Journal* articles
are published Online First, sign up at NEJM.org.